Starbucks (NASDAQ: SBUX) reported a 13% increase in second-quarter adjusted earnings to 60 cents per share, which exceeded analysts’ expectation of 56 cents per share. The announcement sent the shares up 1.5% during after-market trading on Thursday.
SBUX shares have gained 18.7% this year, outperforming the S&P 500 index, which has increased 16.8% during the same period.
On a GAAP basis, net income rose 12.8% to 53 cents per share, helped by a 5% growth in net sales to $6.31 billion. The top line came in line with the street expectation.
Global comparable sales rose 3%, in line with the street projection, driven by a 3% increase in average ticket.
READ: THE CANNABIS-BEVERAGE INDUSTRY IS SOMETHING YOU DON’T WANT TO MISS THIS YEAR
The second-quarter earnings come at a time when the coffee company is facing tight competition in its second-largest market – China. We had earlier reported how Chinese coffee joint Luckin Coffee is offering stiff resistance to Starbucks’ growth, by offering affordable coffee on the go.
Earlier this week, Luckin filed for a US IPO, to reportedly raise up to $800 million. All this has contributed to a recent spike in short interest in SBUX stock.
Outlook
Looking ahead into fiscal 2019, the company expects global comparable store sales growth between 3% and 4%. It is also aiming to open approximately 2,100 net new stores around the globe before the end of this year.
Starbucks raised its guidance for FY2019 Non-GAAP EPS in the range of $2.75 to $2.79. Previously it was projected to be in the range of $2.68 to $2.73.
Outlook for FY2019 GAAP EPS was raised to $2.40 to $2.44 from the prior range of $2.32 to $2.37.
Price target hike
Last week, Andrew Charles of Cowen raised the price target on the coffee chain from $63 to $69. However, the new price is still at a 9% discount from the current trading price.
Browse through our earnings calendar and get all scheduled earnings announcements, analyst/investor conference and much more!
Most Popular
Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO
Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training
INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues
Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came
Riding the AI wave, Nvidia looks set to stay on the high-growth path
After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on
